Spotlight Series on Hepatitis C


Ledipasvir and Sofosbuvir in Hepatitis C Genotype 6: A Pilot Study

April 2015

The combination of ledipasvir + sofosbuvir was highly effective in a small study of people with HCV genotype 6.

Researchers recruited 25 participants with the following average profile:

  • 64% men and 36% women
  • age -- 51 years
  • HCV viral load -- 6.6 log
  • most participants (23) had never previously been exposed to HCV treatment
  • two participants had a severe degree of liver injury (cirrhosis)


After 12 weeks of ledipasvir + sofosbuvir, 96% (24 of 25 participants) achieved an SVR12.

At this time further information about the trial is not available. However, note that the study was small and the results, although very promising, require confirmation in a larger clinical trial.


Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infections. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract LB-11.

This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.